AstraZeneca in talks with Bristol Myers Squibb on $400 billion megadeal, FT reports

AstraZeneca and Bristol Myers Squibb are in talks regarding a potential merger, the Financial Times reported. The deal would be valued at approximately 400 billion dollars. Both companies are major pharmaceutical manufacturers, with AstraZeneca based in the United Kingdom and Bristol Myers Squibb based in the United States.

Next story